Evofem Biosciences (EVFM) Misses Q3 EPS by 34c

Evofem Biosciences (NASDAQ: EVFM) reported Q3 EPS of ($0.71), $0.34 worse than the analyst estimate of ($0.37).

"We have made significant progress this quarter in our clinical programs evaluating Amphora for critical areas in women's health where current options are either insufficient or absent entirely," said Saundra Pelletier, Chief Executive Officer of Evofem. "The last patient visit in the AMPOWER study of Amphora for the prevention of pregnancy is scheduled for this week. This will allow us to proceed with data analyses and keeps us on track to announce top-line results in December of this year, which is a major milestone for Evofem."

"Assuming positive results, Evofem will re-submit the Amphora New Drug Application in the second quarter of 2019. Pending FDA approval, we expect to launch Amphora in January 2020 as the first and only non-hormonal, on-demand, woman-controlled prescription birth control method in the U.S."

For earnings history and earnings-related data on Evofem Biosciences (EVFM) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Cerebras Systems (CBRS) Misses Q1 EPS, Revenues Beat
• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI